C-EHEVGalilei Biosciences
SIRT6 activation, small molecules, neuroprotection
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EHEV
C-EHEVC-EHEVSIRT6 activation, small molecules, neuroprotection
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Galilei Biosciences SIRT6 activation, small molecules, neuroprotection
Galilei Biosciences is developing proprietary small-molecule SIRT6 activators, with glaucoma identified as the primary indication. The deck states that SIRT6 activation has shown neuroprotective, anti-inflammatory, mitochondrial, metabolic, and DNA-repair effects. Its development plan focuses on medicinal chemistry, ADME/PK optimization, in vivo proof of concept, and development-candidate nomination for glaucoma.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Galilei Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (7 programs at preclinical).…
Source: Deterministic